| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e29526f284c0155fd79806c9dd5a1c7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-45 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0619
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0623
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0618
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-907
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4756
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 |
| filingDate |
2019-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f59e6b502fefa7b5715a3dc6f81885de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab00b0839a5d3775bdf3e61ad332e917
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcd82f466e52d4302d1b9377b3b72ffe |
| publicationDate |
2020-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111867617-A |
| titleOfInvention |
Compositions and methods for inducible expression of neurotrophic factors |
| abstract |
Delivery of glial cell line-derived neurotrophic factor (GDNF) has provided benefits to parkinson's disease patients and is currently being tested in a phase 1/2a clinical trial for ALS patients. However, long-term trophic factor delivery shuts down or prevents dose adjustments in the event of side effects. To address this, the inventors designed a stably integrated, third generation doxycycline regulated vector that allows for inducible and reversible expression of therapeutic molecules. Neural progenitor cells derived from human ipscs were stably transfected with the vector, expanded and transplanted into adult mouse brains. The inventors observed that doxycycline addition and removal caused GDNF expression to be induced and reversed multiple times, suggesting that doxycycline could penetrate grafts and modulate transgene expression in vivo. The inventors' findings provide evidence of the concept of combining gene and stem cell therapy to effectively modulate ectopic protein expression in transplanted cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11466290-B2 |
| priorityDate |
2018-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |